Literature DB >> 11920854

Angiotensin converting enzyme gene insertion/deletion polymorphism: case-control association studies in schizophrenia, major affective disorder, and tardive dyskinesia and a family-based association study in schizophrenia.

Ronnen H Segman1, Yami Shapira, Ilan Modai, Adnan Hamdan, Joseph Zislin, Uriel Heresco-Levy, Kyra Kanyas, Shmuel Hirschmann, Osnat Karni, Boris Finkel, Michael Schlafman, Arturo Lerner, Baruch Shapira, Fabio Macciardi, Bernard Lerer.   

Abstract

Angiotensin converting enzyme (ACE) is a candidate gene for psychiatric disorders. We examined the frequency of a functional insertion/deletion (I/D) polymorphism in the 16th intron of the ACE gene (located on chromosome 17q23) in groups of patients with schizophrenia (n = 104 and 113), major depression (n = 55), and bipolar disorder (n = 87) compared to healthy control subjects (n = 87). There was no evidence for allelic or genotypic association of the polymorphism with any of the disorders or with tardive dyskinesia (TD) in patients with schizophrenia. In a sample of nuclear families (n = 61) made up of one or more patients with schizophrenia recruited with their parents, there was no evidence for biased transmission of ACE I/D alleles. Particularly in the case of schizophrenia, these findings do not support an association of the ACE I/D polymorphism with the phenotypes examined. Copyright 2002 Wiley-Liss, Inc.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11920854     DOI: 10.1002/ajmg.10255

Source DB:  PubMed          Journal:  Am J Med Genet        ISSN: 0148-7299


  7 in total

Review 1.  Progress in Elucidating Biomarkers of Antidepressant Pharmacological Treatment Response: A Systematic Review and Meta-analysis of the Last 15 Years.

Authors:  G Voegeli; M L Cléry-Melin; N Ramoz; P Gorwood
Journal:  Drugs       Date:  2017-12       Impact factor: 9.546

2.  Meta-analysis of genetic association studies on bipolar disorder.

Authors:  Fayaz Seifuddin; Pamela Belmonte Mahon; Jennifer Judy; Mehdi Pirooznia; Dubravka Jancic; Jacob Taylor; Fernando S Goes; James B Potash; Peter P Zandi
Journal:  Am J Med Genet B Neuropsychiatr Genet       Date:  2012-05-09       Impact factor: 3.568

3.  Association between the Regulator of G-protein Signaling 9 Gene and Patients with Methamphetamine Use Disorder and Schizophrenia.

Authors:  Y Okahisa; M Kodama; M Takaki; T Inada; N Uchimura; M Yamada; N Iwata; M Iyo; I Sora; N Ozaki; H Ujike
Journal:  Curr Neuropharmacol       Date:  2011-03       Impact factor: 7.363

4.  Association between Insertion/Deletion Polymorphism in Angiotension Converting Enzyme and Susceptibility to Schizophrenia.

Authors:  Hajar Mazaheri; Mostafa Saadat
Journal:  Iran J Public Health       Date:  2015-03       Impact factor: 1.429

Review 5.  Genetic Factors Associated With Tardive Dyskinesia: From Pre-clinical Models to Clinical Studies.

Authors:  Evangelia Eirini Tsermpini; Sara Redenšek; Vita Dolžan
Journal:  Front Pharmacol       Date:  2022-01-24       Impact factor: 5.810

Review 6.  A polygenic score for schizophrenia predicts glycemic control.

Authors:  Han Cao; Junfang Chen; Andreas Meyer-Lindenberg; Emanuel Schwarz
Journal:  Transl Psychiatry       Date:  2017-12-18       Impact factor: 6.222

7.  A study in first-episode psychosis patients: does angiotensin I-converting enzyme (ACE) activity associated with genotype predict symptoms severity reductions after treatment with the atypical antipsychotic risperidone?

Authors:  João V Nani; Caroline Dal Mas; Camila M Yonamine; Vanessa K Ota; Cristiano Noto; Sintia I Belangero; Jair J Mari; Rodrigo Bressan; Quirino Cordeiro; Ary Gadelha; Mirian A F Hayashi
Journal:  Int J Neuropsychopharmacol       Date:  2020-07-22       Impact factor: 5.176

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.